Roche and GSK in MEK/BRAF melanoma combo face off
This article was originally published in Scrip
Roche/Genentech and GlaxoSmithKline have both presented new data on their MEK/BRAF inhibitor combination regimens in their battle for BRAF V600 mutation-positive melanoma market at ESMO. Overall the two companies' regimens are set to change the standard of care for this indication, and with the efficacy profiles looking too tight to call, it seems that the relative side effect profiles of the two regimens will determine their eventual success.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.